DDInter1860 DDInter1824
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.
Triazolam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Theophylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Clonazepam
Clonazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Flunitrazepam
Flunitrazepam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Clonazepam
Clonazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Lorazepam
Lorazepam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Theophylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Triazolam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Canakinumab {u} may lead to a major life threatening interaction when taken with {v} Tocilizumab
Triazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Midazolam (Compound) and Midazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Flunitrazepam (Compound) and Flunitrazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Midazolam (Compound) and Midazolam may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Triazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab